A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation

Yang Lv, BSMa, Lin He, PhDb, Chao Wang, PhDc, Liju Zhang, PhDb, Biyuan Zhang, MDd, Yuhua Song, MDb,*

Abstract
Background: To integrate relevant clinical data of multicatheter accelerated partial breast irradiation (mAPBI) for reaching a comprehensive conclusion.

Methods: We did 3 meta-analyses for clinical outcomes including 1740 women from 4 articles, for acute radiotherapy (RT)-associated toxicity including 1255 patients from 5 articles, and for late RT-related toxicity involving 1565 patients from 9 papers. Clinical outcomes analyses were stratified by molecular subtypes, lymph nodes status, receptor status, and human epidermal growth factor receptor 2 (HER2) status.

Results: For the Luminal A/B phenotypes, the disease relapse and failure in survival significantly decreased when compared with triple negative (TN)/HER2-amplified subtypes (P < .00001). The 5-year regional nodal recurrence (RNR), 5-year distant metastasis-free survival (DMFS) and 5-year disease free-survival (DFS) of TN patients were significantly superior to HER2-overexpression patients (P < .00001). The 5-year cause-specific survival (CSS), 5-year DMFS and 5-year overall survival (OS) in women with lymph nodes-negative were significantly improved versus patients with lymph nodes-positive (P = .0001). Conversely, the positive status of HER2 compared with negative one significantly increased the rate of local recurrence (LR) (P = .02). For acute toxicity, the morbidity of dermatitis was significantly higher than hematoma and implant infection (P = .01, P < .0001, respectively). For late toxicity, the occurrences of fibrosis (32%) and telangiectasia (14%) were significantly higher than other complications (P < .0001).

Conclusion: HER2-enriched subtype compared with other subtypes has significantly increased disease relapse and failure in survival. HER2-positive status is positively associated with an increased incidence of LR. Dermatitis is the most common acute RT-related toxicity and fibrosis is the first late RT-related toxicity.

Abbreviations: APBI = accelerated partial breast irradiation, CSS = cause-specific survival, DFS = disease free-survival, DMFS = distant metastasis-free survival, HER2 = human epidermal growth factor receptor 2, IBTR = ipsilateral breast tumor relapse, LR = local recurrence, LRR = locoregional recurrence, mAPBI = multicatheter APBI, OS = overall survival, RNR = regional nodal recurrence, RT = radiotherapy, TN = triple negative, WBI = whole breast irradiation.

Keywords: clinical outcomes, mAPBI, RT-related toxicity, systematic review

1. Introduction

Given that the pathological data and patterns of failure indicate the residual tumor and clinical recurrence mainly limited to the tissues adjacent to the tumor-resection cavity in patients with early stage breast cancer, the notion of accelerated partial breast irradiation (APBI) is emerged as the times require.11–8 APBI is considered as an accelerated 1-week treatment course using a dose-fractionation scheme simulated by radiobiology and suitable for eliminating the residual tumor surrounding the lumpectomy cavity.8 This method greatly shortens the radiotherapy course and significantly decreases the required irradiation volume of mammary gland, whose tumor control and the effects of late radiotherapy (RT)-related toxicity are alike to the conventional whole breast irradiation (WBI).119 Since these advantages of it, an increasing number of women are inclined to accept APBI instead of WBI. Thereby, several novel APBI technologies have been developed in the past few years, which can be roughly divided into 4 categories: multicatheter APBI (mAPBI), intraoperative radiotherapy with electrons, spherical balloon or metal devices, and external-beam conformal technique.19 The mAPBI treatment, one of the early approaches to explore the notion of APBI, has gathered most ample clinical data with...
long period follow-up and is feasible for most patients compared with other APBI techniques, but not the perfect technology for all cases.[11] Nevertheless, effective tumor control and good-to-excellent cosmetic outcomes are brought by mAPBI when appropriate knowledge and technology are available. At present, the main problems in the scientific evaluation of mAPBI as a therapeutic strategy are to demarcate and perfect its indications. To settle this issue, this article puts emphasis on investigating the clinical results by meta-analysis in the subclassifications treated with mAPBI, including molecular phenotypes, the status of hormone receptor, lymph nodes and human epidermal growth factor receptor 2 (HER2), as well as the toxicity related to RT.

2. Methods

2.1. Study design

The keywords—[(multicatheter accelerated partial breast irradiation) OR (multicatheter accelerated partial breast irradiation) OR (multicatheter accelerated partial breast irradiation) OR (multicatheter accelerated partial breast irradiation) OR—were retrieved in the following databases-PubMed, Cochrane library, Embase and Web of Science-by 2 authors independently. The included articles were supposed to meet the following criteria: clinical studies published in English; early stage breast cancer patients treated with mAPBI; reporting the case number of clinical outcomes (survival and/or relapse) or RT-related toxicity. The exclusion criteria were involving: nonclinical trials; the study classification was incorrect; the absence of the forementioned event count or other information that could be used to calculate the event count in the paper; the absence of the forementioned event count or other information that could be used to calculate the event count in the publication.

Furthermore, data were extracted from included studies and were statistically analyzed in accordance with forementioned subgroups. Generally, triple negative (TN) and HER2-overexpression diseases have poor clinical prognosis compared with Luminal A/B tumors. Therefore, we subdivided the molecular phenotype subclassification into 2 comparative cohorts, Luminal A/B subtype vs TN/HER2-enriched subtype, and TN phenotype vs HER2-enriched phenotype. Meanwhile, the remaining subgroups were analyzed in terms of status positivity vs negativity.

2.2. Statistical analysis

In this article, the clinical outcomes were mainly analyzed on 5-year disease recurrence [i.e., ipsilateral breast tumor relapse (IBTR), regional nodal recurrence (RNR), local recurrence (LR) and locoregional recurrence (LRR)] and 5-year survival [such as overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and cause-specific survival (CSS)]. OS was defined as the time from diagnosis to death or final follow-up; the definition of DFS was the period from diagnosis to disease relapse; DMFS was calculated by the period from diagnosis to distant metastasis; CSS referred to the length of time from diagnosis to death from the cancer. The disease recurrence was calculated directly by the number of events; the incidence of failure in survival was analyzed by a postprocessing value that was computed by subtracting survival cases from total sample sizes. We scrutinized the included studies and did not find concrete number that described the association between RT-related toxicity with designed subgroups. Therefore, the comparison of their morbidity was statistically calculated by ANOVA analysis and LSD-test. These analyses were programmed via Review Manager (version 5.3) and SPSS (version 23.0).

3. Results

3.1. Article and patient characteristics

After layers of screening, which was shown in Figure 1, we finally obtained 4 articles[12–15] with 1740 women for clinical outcomes analysis, 7 trials[16–22] with 1255 people for acute RT-related toxicity analysis as well as 10 studies[16–25] with a total of 1565 patients for late RT-related toxicity analysis. Of the patients who were reported the association between molecular subtypes and clinical outcomes, 1166 (84.2%) had Luminal A/B breast cancer, 154 (11.1%) were classified into TN disease, 64 (4.6%) suffered from HER2-enriched breast tumor. A total of 861 women were collected to cover how the lymph nodes status influenced on the tumor relapse and failure in survival, in whom 72 (8.4%) had lymph nodes positivity and 789 (91.6%) had lymph nodes negativity. We gathered 140 patients with information of receptor status, of whom were assorted into following categories: 91 with positive ER status, 49 with negative ER status; 85 with positive PR status, 55 with negative PR status; 23 with HER2 positivity and 117 with HER negativity. Regarding the analysis of RT-related toxicity, we recruited 1255 women for acute toxicity and 1565 patients for late toxicity. Other details of patient characteristic had provided in Supplemental Tables 1–3 (Appendix, page 1–2, http://links.lww.com/MD/C801).

3.2. Clinical outcomes

For women with Luminal A/B phenotypes, the disease relapse and failure in survival were significantly decreased when compared to patients with TN and/or HER2-amplified subtypes (P < .00001). However, no statistical differences in 5-year LR and 5-year LRR were observed between them (Fig. 2A). Furthermore, the comparison of TN subtype vs HER2-enriched subtype showed that some clinical outcomes in former were significantly perfected (P < .00001), manifesting as a reduced 5-year RNR coupled with the increased 5-year DFS and DMFS (Fig. 2B).

As seen in Figure 3, there were significant improvements of the 5-year CSS, 5-year DMFS and 5-year OS in negative lymph nodes patients compared with positive status (P = .0001). Still, no difference of 5-year LR and LRR were detected between the 2 properties of lymph nodes.

As shown in Figure 4, the rate of LR in positive ER and positive PR had a reduced tendency by comparison with negative ones (P = .06, P = .07, respectively). Conversely, the positive HER2 status compared with negative one significantly increased the rate of LR (P = .02).

3.3. Radiotherapy-related toxicity

As presented in Figure 5A, the highest morbidity of acute toxicity was dermatitis, which was more frequent than hematoma and implant infection (P = .01, P < .0001, respectively), but without significant difference by comparison of breast pain (P = .58). In terms of late toxicity outlined in Figure 5B, the morbidity of fibrosis (32%) and telangiectasia (14%) was significantly higher than other complications, especially in seroma (P < .0001). The additional analyses of RT-induced adverse effect were provided in Supplemental Table 4 (Appendix, page 3, http://links.lww.com/MD/C801).
4. Discussion

Several meaningful findings were presented in our study when mAPBI was utilized to treat early stage breast cancer patient. The disease recurrence and failure in survival in Luminal A/B cohort are significantly lower than TN/HER2-overexpression cohort, and in TN tumor are significantly attenuated by comparison with HER2-amplified breast cancer. Hence, the clinical outcomes of HER2-enriched breast tumor are located in the most unfavorable position. In addition, patient with negative lymph nodes significantly reduces the failure in survival when compared to patient with positive lymph nodes, despite no difference of LR and LRR between them. In the case of LR, compared to negative HER2 status, the positive one is a risk factor for significantly increasing its incidence.

APBI is a worthwhile popularizing treatment approach, which greatly shortens RT duration in comparison to WBI, and has the merit of effectively reducing the radiation exposure to breast, skin, lung, and cardiac tissue especially.[26] To our knowledge, the LR incidence and failure in survival of mAPBI are comparable to WBI, which has been demonstrated by results from 2 randomized trails (the GEC-ESTRO trail[27] and the William Beaumont Hospital group trail).[28] In the GEC-ESTRO trail, there was no significant difference between mAPBI with WBI of the cumulative rate of 5-year LR (1.38% vs 0.97%; P = .53) 5-year regional recurrence (0.48% vs 0.18%; P = .39) and 5-year DM (0.80% vs 0.93%; P = .81). Besides, both treatments had promising 5-year DFS (P = .79) and 5-year OS (P = .11), with no significant difference as well. Similarly, in the William Beaumont Hospital group trail, which conducted a matched-pair analysis that treated 199 patients with WBI and an identical number of women with mAPBI, no differences were shown between WBI with mAPBI in the 12-year incidences of LR (3.8% vs 5.0%, P = .40), regional recurrence (0% vs 1.1%, P = .15), DFS (87% vs 91%, P = .30), CSS (93% vs 95%, P = .28), as well as OS (78% vs 71%, P = .06), respectively. Moreover, they also performed a univariate analysis on mAPBI cohort, discovering that there was no association between LR with tumor size, ER status, PR status,

Figure 1. The flow diagram regards to the selection procedure of included articles.
adjuvant chemotherapy, lymph nodes status, or margin status, which is consistent with our outcomes.

Some literatures have provided clinical results regarding the impact of molecular subtypes on early-stage breast tumor with mAPBI strategy. As analyzing the incidence of DFS, CSS, and OS, it indicated that HER2-amplified subtype had significantly reduced them when compared with the Luminal subtypes. In the study of Anderson,[14] with a median follow-up of 5.4 years, it was showed that the 5-year IBTR incidence was 4.7% overall, 3.5% for Luminal A, 4.1% for Luminal B, 13.3% for HER2-overexpression, and 11.3% for TN subtype. Also, Luminal A subtype was in a lower risk of 5-year IBTR than other subtypes pooled (3.5% vs 7.3%; \( P = .02 \)). As for the 5-year RNR with a rate of 2.1% overall, which was 3.5% for Luminal A, 5.2% for Luminal B, 34.5% for HER2 and 11.3% for TN phenotype, it increased for patients with HER2-enriched subtype compared to other molecular subtypes pooled and for Luminal B versus Luminal A phenotype. Similarly, we have proved that HER2-expression subtype has poor clinical results, even compared with highly invasive TN subtype. Accordingly, it is believed that the clinical outcomes of early stage breast cancer women with HER2-amplified subtype locate in the inferior position when treated with mAPBI.

Up till now, the first large-scale study in regard to the effect of lymph node status on clinical outcomes of APBI in treating breast cancer was initiated by William Beaumont Hospital in 2011,[29] which enrolled 471 lymph node-negative and 39 lymph node-positive breast cancer patients. With a median follow-up of 7.8 years for node-positive status and 6.3 years for node-negative status, no significant difference was detected between them in 5-year axillary failure, DFS and OS (0% vs 0%, \( P = .69 \); 90.0% vs 88.0%, \( P = .79 \); 91.0 vs 84.0%, \( P = .65 \); respectively). It indicated, however, the 5-year regional relapse and distant metastasis in the node-positive women were significantly higher than node-negative women (6.1% vs 0%, \( P < .001 \); 8.9% vs 2.2%, \( P = .005 \); respectively). The CSS at 5 years showed an

---

**Figure 2.** The comparison in molecular subtypes of disease recurrence and failure in survival. (A) Luminal A/B vs TN/HER2-enriched; (B) TN vs HER2-enriched. a: The event is the number of the failure in survival.
increasing trend in node negativity cohort compared to node positivity cohort (98% vs 90%; *P* = .06). Combined with our results, the failure in survival is further reduced when treated with APBI via multilumen interstitial brachytherapy, especially for 5-year CSS, DMFS, and OS in node-negative women.

Several oncologists have researched the prognostic factors affecting the incidence of LR in breast patients with APBI treatment.[30,31] In the study of Cannon et al,[32] a poor prognostic factor is ER negative status, independently related to increased risk of LRR, which is matched with our outcomes. A small number of studies have also evaluated the effect of HER2 status on the LR rate. Hattangadi-Gluth et al[33] report the identical results as our conclusion, whose study shows that the LR rate of HER2-positive tumor is significantly higher than negative one.

Furthermore, we systematically assessed the RT-related toxicity in women underwent mAPBI. In the acute toxicity, the first common complication is dermatitis, and the lowest one is the implant infection. In the late toxicity, fibrosis takes the highest incidence, and least frequent complication is seroma.

The GEC-ESTRO trial recruited 1182 low-risk patients to compare the results of RT-associated toxicity between WBI approach (n = 552) with mAPBI approach (n = 663), which illustrated that the mAPBI group had a significantly lower incidence of dermatitis than WBI group (Grade1–3, 19.2% vs 92%; *P* < .0001), but with a significantly increased morbidity of hematoma (Grade1–2, 20% vs 2.2%; *P* < .0001) and implant infection (Grade 1–3, 4.7% vs 2.2%; *P* = .005). There was no statistical difference between the 2 ways induced breast pain (*P* = .23).[34] Different from our results, this study concludes that breast pain is the first common complication induced by mAPBI and reports an incremental morbidity of hematoma and dermititis. However, the implant infection has the lowest incidence of all acute toxicities, which is concordant to our results. Some reports conclude that the rate of implant infection is between 0% and 11%.[35–40] All patients who accept skin antiseptics and oral antibiotic prophylaxis daily for at least 8 days
can effectively avoid its occurrence that mainly limited to the entry and exit points of the after-loading tube.\cite{41}

Regarding the late RT-related toxicity followed by treatment with mAPBI, the published literatures mainly focus on describing the incidence of telangiectasias, fibrosis and fat necrosis. Some working groups report that the incidence of telangiectasias ranges from 3.7% to 22.7%,\cite{35,42} with an increased trend as time changing, the rate of fibrosis that occurs most frequently is between 29.5%-42.2%,\cite{35,42} as well as morbidity of fat necrosis ranges from 2.3% to 24.2%,\cite{35,40} which are all matched with us. It is worth noting that fibrosis is a combined sequela from postoperative changes and irradiation effects.\cite{35,43,44} Thus, it is difficult to estimate whether the high incidence of this complication is entirely caused by radiotherapy. In the future, we can compare the occurrence of fibrosis between APBI therapy alone with APBI therapy plus surgery to judge the extent of operational effects on its formation according to the difference between the 2 arms.

5. Conclusion

For the early stage breast cancer patients treated with mAPBI therapy, HER2-overexpression subtype compared with other subtypes has a significantly increased disease recurrence and failure in survival, of which in lymph node-positive status is also significantly higher than the negative one. In addition, HER2-positive status is associated with increased rate of LR. The most common acute RT-related toxicity is dermatitis and the first rife late RT-associated toxicity is fibrosis.

Author contributions

Data curation: Biyuan Zhang.
Funding acquisition: Yuhua Song.
Investigation: Biyuan Zhang.
Methodology: Biyuan Zhang.
Project administration: Lijiu Zhang.
Resources: Lin He, Lijiu Zhang.
References

[1] Favert D, Holland R, Burgers L. An original stereomicroscopic analysis of the mammary glandular tree. Virchows Arch A Pathol Anat Histopathol 1992;421:115–9.

[2] Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys 1993;27:575–83.

[3] Imamura H, Haga S, Shimizu T, et al. Relationship between the morphological and biological characteristics of intraductal components accompanying invasive ductal breast carcinoma and patient age. Breast Cancer Res Treat 2000;62:177–84.

[4] Ohtake T, Abe R, Kimijima I, et al. Intraductal extension of primary invasive breast carcinoma treated by breast-conservative surgery. Computer graphic three-dimensional reconstruction of the mammary duct-lobular systems. Cancer 1995;76:32–45.

[5] Clark RM, Wilkinson RH, Maceli PN, et al. Breast cancer. Experiences with conservation therapy. Am J Clin Oncol 1987;10:461–8.

[6] Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast cancers: long-term results of a randomized trial. Ann Oncol 2001;12:997–1003.

[7] Uppsala-Orebro Breast Cancer Study G. Sector resection with or without postoperative radiotherapy for stage, L, breast cancer: a randomized, trial. J Natl Cancer Inst 1990;82:277–82.

[8] Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol 2003;120:500–27.

[9] Sarin R, Chopra S. Accelerated partial breast irradiation using multicatheter brachytherapy. Nature Clin Pract Oncol 2007;4:382–3.

[10] Sarin R. Partial-breast treatment for early breast cancer: emergence of a new paradigm. Nature Clin Pract Oncol 2005;2:40–7.

[11] Hupel JT, Wazer DE. A comparison of brachytherapy techniques for partial breast irradiation. Brachytherapy 2012;11:163–75.

[12] Wadasadawala T, Mondal M, Paul SN, et al. Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort. J Contemp Brachytherapy 2018;10:47–57.

[13] Kamrava M, Kuske RR, Anderson B, et al. Outcomes of node-positive breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: The Pooled Registry of Multicatheter Intestinal Sites (PROMIS) experience. Am J Clin Oncol 2018;41:538–43.

[14] Anderson BM, Kamrava M, Wang PC, et al. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry of Multicatheter Intestinal Sites research group. Brachytherapy 2016;15:788–95.

[15] Budruckar A, Gurram L, Upreti RR, et al. Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3 dimensional computerized tomography based brachytherapy. Radiother Oncol 2015;115:349–54.

[16] Artiest C, Maranzano E, Lancellotta V, et al. Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study. Radiother Oncol 2017;124:208–13.

[17] Ott OJ, Hildebrandt G, Poter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: Local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiat Oncol 2007;2:281–6.

[18] Latorre JA, Galdos P, Buznego LA, et al. Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results. J Contemp Brachytherapy 2018;10:38–63.

[19] Hannoun-Levi JM, Cham Kee DE, Gal J, et al. Accelerated partial breast irradiation for suitable elderly women using a multicatheter interstitial high-dose-rate brachytherapy: early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase II/II trial. Brachytherapy 2018;17:407–14.

[20] Strand V, Hildebrandt G, Poter R, et al. Accelerated partial breast irradiation: 5-year results of the German–Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011;80:17–24.

[21] Sumodhie S, Levy J, Chamorey E, et al. Accelerated partial breast irradiation for elderly women with early breast cancer: a compromise between whole breast irradiation and omission of radiotherapy. Brachytherapy 2017;16:929–34.

[22] Cuttino LW, Arthur DW, Vicini F, et al. Long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial. Int J Radiat Oncol Biol Phys 2014;90:1025–9.

[23] Hannoun-Levi JM, Resch A, Gal J, et al. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol 2013;108:226–31.

[24] Polgar C, Major T, Fodor J, et al. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 2010;94:274–9.

[25] Yeo SG, Kim J, Kwak GH, et al. Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity. Radiat Oncol (London, England) 2010;5:56.

[26] Lettmaier S, Kreppler S, Lotter M, et al. Radiation exposure of the heart, lung and skin by radiation therapy for breast cancer: a dosimetric comparison between partial breast irradiation using multicatheter brachytherapy and whole breast teletherapy. Radiother Oncol 2011;100:189–94.

[27] Strand V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet (London, England) 2016;387:229–38.

[28] Shah C, Antonucci JV, Wilkinson JB, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 2011;100:210–4.

[29] Shah C, Wilkinson JB, Shattelman S, et al. Impact of lymph node status on clinical outcomes after accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2012;82:e409–414.

[30] Vargo JA, Verma V, Kim H, et al. Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity. Int J Radiat Oncol Biol Phys 2014;88:285–91.

[31] Patel RR, Christensen ME, Hodge CW, et al. Clinical outcome analysis in high-risk patients eligible for national surgical adjuvant breast and bowel B-39/radiation therapy oncology group 0413 trial: five-year results. Int J Radiat Oncol Biol Phys 2008;70:970–3.

[32] Cannon DM, McHaffie DR, Patel RR, et al. Locoregional recurrence following accelerated partial breast irradiation for early-stage invasive breast cancer: significance of estrogen receptor status and other pathological variables. Ann Surg Oncol 2013;20:3446–52.

[33] Hattangadi-Gluth JJ, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys 2012;82:1185–91.

[34] Ott OJ, Strand V, Hildebrandt G, et al. GEC-ESTRO multicenter phase 3 trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Oncol 2016;120:119–23.

[35] Arthur DW, Koo D, Zwicker RD, et al. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys 2003;56:681–9.

[36] Baglan KL, Martinez AA, Frazier RC, et al. The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2001;50:1002–11.

[37] Chen PY, Vicini FA, Benitez P, et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer 2006;106:991–9.

[38] Lowenda BD, Taghan AG, Kachnic LA, et al. Dose-volume analysis of radiotherapy for T1NO invasive breast cancer treated by local excision and partial breast irradiation by low-dose-rate interstitial implant. Int J Radiat Oncol Biol Phys 2003;56:671–80.
[39] Perera F, Engel J, Holliday R, et al. Local resection and brachytherapy confined to the lumpectomy site for early breast cancer: a pilot study. J Surg Oncol 1997;65:263–7. Discussion 267-268.

[40] Wazer DE, Berle L, Graham R, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys 2002;53:869-97.

[41] Ott OJ, Hildebrandt G, Potter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: Local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol 2007;82:281–6.

[42] Polgar C, Major T, Fodor J, et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 2004;60:1173–81.

[43] Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 2002;9:543–5.

[44] Borger JH, Kemperman H, Smitt HS, et al. Dose and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol Phys 1994;30:1073–81.